Results, reports and publications
Latest results
Clariant delivers continued strong results in volatile operating environment – Court dismisses Shell’s damage claim related to the 2020 competition law infringement
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
- Q2 2026 comparable sales rose 0.6 % in local currencies to CHF 941.3 million and declined reported 0.3 % when including portfolio pruning. Care Chemicals recorded strong growth of 4.2 % excluding pruning and Adsorbents & Additives of 5.3 %, which more than offset lower Catalysts’ sales of - 13.3 % due to the Middle East conflict
- Q2 2026 EBITDA margin before exceptional items increased by 80 basis points to 18.2 % from 17.4 % in Q2 2025 with strong performance in Care Chemicals more than offsetting lower Catalysts’ margins
- H1 2026 sales of CHF 1 859.3 million flat in local currencies excluding portfolio pruning, - 1.2 % reported; EBITDA margin before exceptional items of 17.8 % versus 18.1 % in the prior year, with Care Chemicals and Adsorbents & Additives offsetting most of the Middle East impact on Catalysts
- H1 2026 operating cash flow of CHF 168.7 million versus CHF 115.9 million in the prior year, driven by effective net working capital management and disciplined Capex; free cash flow conversion improved by 15 percentage points to 52 % (LTM)
- Further active cost management increases the ongoing performance improvement programs by CHF 20 million to an annual run-rate total of CHF 100 million, CHF 90 million in 2026; one-time restructuring charges amount to CHF 29 million
- Guidance 2026 remains unchanged
- Clariant dismissed from Shell’s allegations related to the 2020 competition law infringement. The Court particularly found no proof that the information exchange among buyers caused market harm or altered pricing metrics like the Monthly Contract Price (MCP).
- Amsterdam court also dismissed a claim seeking declaratory judgment of liability of the defendants for the same conduct brought by a claim vehicle »Stichting Ethylene Claims«
“In the second quarter of 2026, Clariant continued to deliver strong results, demonstrating resilience in a volatile operating environment. Comparable sales increased by 0.6 % in local currency with strong pricing-led growth in Care Chemicals and Adsorbents & Additives offsetting volume headwinds in Catalysts from the ongoing conflict in the Middle East. Our EBITDA margin before exceptional items improved by 80 basis points to 18.2 %, driven by Care Chemicals, which more than offset the headwinds in Catalysts. We are expanding our performance improvement programs by over CHF 20 million to run-rate savings of CHF 100 million by 2027, with 90 % of the total expected to be achieved by the end of 2026,” said Conrad Keijzer, Chief Executive Officer of Clariant.
“Our guidance for 2026 remains unchanged with sales around flat in local currency and EBITDA margin before exceptional items of around 18 %. While the Middle East conflict continues to weigh particularly on our Catalysts business, we expect a stronger second half in the business as customers particularly outside the Middle East resume
operations. We continue to successfully implement our proven value-based price initiatives by leveraging our differentiated, innovative solutions for customers, securely supplied through our global production networks,” Conrad Keijzer added.
1 All references to local currency growth, pricing, volumes, and scope exclude the impact from hyperinflation countries Argentina and Türkiye. All references to currency include a net impact from hyperinflation countries Argentina and Türkiye.
Read more
Upcoming results
On 31 July 2026, Clariant will present its Second Quarter / First Half Year Results 2026.
The results will be published at 7.00 am CEST and a conference call and webcast for analysts and investors will start at 1.00 pm CEST.
Conference call participants are kindly requested to register here.
Results center
Please use the results center to find Clariant’s financial results and associated documents as published in the last five years
Q1 Q2 Q3 Q4 Date 29 April 2025 31 July 2025 30 October 2025 26 February 2026 Quiet period as of 10 April as of 9 July as of 8 October as of 19 January 2026 Media release EN EN EN EN Analyst presentation EN EN EN EN Webcast Audio recording MP3 MP3 MP3 MP3 Transcript EN EN EN EN Financial Review / HY report EN - XLS EN - XLS Annual report EN
Q1 Q2 Q3 Q4 Date 30 April 2024 30 July 2024 29 October 2024 28 February 2025 Quiet period as of 11 April as of 10 July as of 9 October as of 10 January 2025 Media release EN EN EN EN Analyst presentation EN EN EN EN Webcast Audio recording MP3 MP3 MP3 MP3 Transcript EN EN EN EN Financial Review / HY report EN - XLS EN - XLS Annual report EN
Q1 Q2 Q3 Q4 Date 5 May 2023 28 July 2023 30 October 2023 29 February 2024 Quiet period as of 17 April as of 10 July as of 10 October as of 15 January Media release EN — DE EN — DE EN — DE EN — DE Analyst presentation EN EN EN EN Webcast Audio recording MP3 MP3 MP3 MP3 Transcript EN EN EN EN Financial Review / HY report EN EN — XLS Annual report EN
Q1 Q2 Q3 Q4 Date 15 June 2022 28 July 2022 27 October 2022 2 March 2023 Quiet period as of 11 July as of 10 October as of 17 February Media release EN — DE EN — DE EN — DE EN — DE Analyst presentation EN EN EN EN Webcast Audio recording MP3 MP3 MP3 MP3 Transcript
EN Financial Review / HY report EN EN Annual report EN
Conferences and roadshows
Clariant's management and Investor Relations team regularly participates in conferences and roadshows. Below you can find an overview of the presentations provided at such events in the last two years.
For an overview of upcoming events, please refer to the Financial calendar.